Skip to main content
Log in

Secondary Amyloidosis in a Patient with Long Duration Crohn's Disease Treated with Infliximab

  • Case Report
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Systemic AA amyloidosis is a serious complication of many chronic inflammatory disorders. Its association with Crohn's disease implies that the inflammatory burden is high enough for amyloid fibrils to form deposits in tissues. A case is presented in which this complication occurred while the patient was clinically well, with biological and endoscopic markers showing an inactive or mildly active disease under anti-tumor necrosis factor alpha therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Stokes M, Foster K, Markowitz G, et al. Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20: 1400–6

    Article  PubMed  CAS  Google Scholar 

  2. Lizuka M, Konno S, Horie Y, et al. Infliximab as a treatment for systemic amyloidosis associated with Crohn's disease. Gut 2006; 55: 744–5

    Article  Google Scholar 

  3. Lachmann H, Goodman H, Gilbertson J, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356: 2361–71

    Article  PubMed  CAS  Google Scholar 

  4. Basturk T, Ozagari A, Osturk T, et al. Crohn's disease and secondary amyloidosis: early complication? A case report and review of the literature. J Renal Care 2009; 35(3): 147–50

    Article  Google Scholar 

  5. Denis MA, Reenaers C, Fontaine F, et al. Assessment of endoscopic activity index and biologic inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflamm Bowel Dis 2007; 13(9): 1100–5

    Article  PubMed  Google Scholar 

  6. Vermeire S, Van Assche G, Rutgeerts P. The role of mucosal healing in the treatment of Crohn's disease and ulcerative colitis. Eur Gastroenterol Rev 2007; 10–11

  7. Tada S, Iida M, Yao T, et al. Intestinal pseudo-obstruction in patients with amyloidosis: clinicopathologic differences between chemical types of amyloid protein. Gut 1993; 34: 1412–17

    Article  PubMed  CAS  Google Scholar 

  8. Boscá M, Pérez-Baylach C, Solis M, et al. Secondary amyloidosis in Crohn's disease: treatment with tumour necrosis factor inhibitor. Gut 2006; 55(2): 294–5

    Article  PubMed  Google Scholar 

  9. Dember L, Hawkins P, Hazenberg B, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007; 356(23): 2349–60

    Article  PubMed  CAS  Google Scholar 

  10. Sandborn W, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab —a randomized trial. Ann Intern Med 2007; 146(12): 829–39

    PubMed  Google Scholar 

  11. Horie Y, Chiba M, Miura K, et al. Crohn's disease associated with amyloidosis successfully treated with an elemental diet. J Gastroenterol 1997; 32: 663–7

    Article  PubMed  CAS  Google Scholar 

  12. Lovat B, Madhoo S, Pepys M, et al. Long-term survival in systemic A amyloidosis complicating Crohn's disease. Gastroenterology 1997; 112: 1362–5

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Dr Fidalgo received honoraria for the submission of the case report, which was funded by Schering-Plough/MSD Portugal. The other authors declare no potential conflicts of interest relevant to this case report. Editorial assistance was provided by Ray Hill of inScience Communications, a Wolters Kluwer business, on behalf of Schering-Plough/MSD Portugal.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Catarina Andrade Fidalgo MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fidalgo, C.A., Calado, J. & Cravo, M. Secondary Amyloidosis in a Patient with Long Duration Crohn's Disease Treated with Infliximab. BioDrugs 24 (Suppl 1), 15–17 (2010). https://doi.org/10.2165/11586250-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11586250-000000000-00000

Keywords

Navigation